















 Human is not a uni-organism but an integrated multi-organisms with numerous microbiota 
distributed from skin surface to intraluminal mucosa of the body. The digestive tract, especially, 
contains totally one billion of bacteria, and the whole of them weighs over 1.5 kilogram. The total 
amount of enterobacterial DNA is almost hundred times more than that of the host. The enterobacteria 
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“core microbiota”、後者を “variant microbiota”















 It has been noted that human intestinal microbiota is in static and synergistic relationship with the 
host. But recent progress of the enterobacterial research with DNA analysis clarified the more dynamic 
and strong correlation between the flora and the host.
 Not only digestive diseases but metabolic, immunologic, cancerous, and mental ones  can be 
attributed to the disorder of intestinal microbiota. In this paper, status quo of the microbiota 
investigation correlating with the diseases is reviewed and the new clinical treatment of probiotics, 
prebiotics and fecal transplantation are introduced.
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Biological self - defense (barrier) system of the gut
Nonspecific defense system
1. Mechanical/Physical mechanism
・ bowel movement (excretion, peristalsis)
・ intestinal villi (covering, movement)
・ integration of intestinal epithelial cells
・ tight junction of the intestinal cells
・ cytocidal activity of phagocytic cells (monocyte/macrophage, neutrophil, etc)
2. Chemical mechanism
・ mucous secretion 
(mucin glycochain, lysozyme, lactoferrin, peroxydase, surfactant, etc)
・ defensin (cryptidine) secreted by paneth cells 
Specific defense system
1. Humoral immunity
・ antigen presenting cells (APC : monocyte/macrophage, dedritic cell, B cell, etc)  
・ IELs (intraepithelial cells : αβ-T cells, γδ-T cells)
・ LPL (lamina propria lymphocytes : Th1/Th2, CTL)
2. Cellular immunity
・ secretory IgA production 

































































図１　腸管栄養と bacterial translocation ９）
Wistar 系雄性ラット（15匹）を自由摂食群（Control 
group）、経腸栄養群（EN:enteral nutrition group）、お














Bacteroides*  P < 0.05
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E. coli








































































糞便移植 回以上 VCM投与 VCM+腸管洗浄
n=13n=13n=16n=16
治癒率




ることにより成立するという仮説（Day CP, James 
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